The results indicated that patients who developed cataracts as an adverse drug reaction had a significantly higher likelihood of persistent anti-Dsg1 antibody positivity (OR = 37.67; 95%CI: 1.88-756.27, P = 0.018). Here, DSG1 is linked to cataract.